You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

oxaliplatin

( ox-AL-ih-plah-tin )
Funding:
Evidence Building Program
  • Oxaliplatin (EBP) - Colorectal Cancer Patients with Resectable or Potentially Resectable Extrahepatic Metastases
  • Oxaliplatin (EBP) - Supplemental 1
  • Oxaliplatin (EBP) - Supplemental 2
New Drug Funding Program
  • Oxaliplatin and Irinotecan - Advanced Pancreatic Cancer (FOLFIRINOX)
  • Oxaliplatin - Adjuvant Colorectal Small Bowel or Appendiceal Cancer
  • Oxaliplatin - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
  • Oxaliplatin - With Surgery for Curative Intent for CRC SBAC Pts with Resectable or Potentially Resectable Liver Mets
  • Oxaliplatin - Second Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
Other Name(s): Eloxatin®
Appearance: clear, colourless solution mixed into larger bags of fluids

You might also be interested in